Derm Dispatch: Systemic Mastocytosis Advocate Shares Diagnostic Delays, Multisystem Burden, and the Impact of Targeted Therapy

WATCH TIME: 31 minutes | Captions are auto-generated and may contain errors.

In the latest episode of the Derm Dispatch series, host Renata Block, DMSc, MMS, PA-C, sat down with indolent systemic mastocytosis patient advocate Suki Tipp to examine the clinical, emotional, and financial toll of delayed diagnosis—and the critical role dermatology clinicians can play in recognizing this rare disease earlier.

Tipp’s symptoms began in 2015 with intensely pruritic lesions on her legs that she initially attributed to shaving or environmental exposures. Red, hive-like eruptions evolved into persistent brown macules, which were initially dismissed as folliculitis with postinflammatory hyperpigmentation. At the time, she did not associate her cutaneous findings with systemic symptoms, including flushing, severe gastrointestinal pain, diarrhea, headaches, and mood changes. As she described, the episodic and seemingly disconnected nature of her manifestations made pattern recognition difficult—not only for her, but for the clinicians she encountered.

Following a life-threatening anaphylactic event triggered by a wasp sting—resulting in critical care admission—Tipp was referred to an allergist who suspected systemic mastocytosis. However, subspecialty care remained fragmented. A requested skin punch biopsy was deferred after dermatologic evaluation deemed the lesions inconsistent with mastocytosis. Meanwhile, her condition escalated dramatically. At her worst, Tipp required 99 epinephrine auto-injectors in a single year due to recurrent anaphylaxis triggered by foods, environmental exposures, and even airborne irritants. She became unable to work and was limited to a handful of “safe” foods and select bottled water products.

Throughout the diagnostic process, collaboration among specialties was limited. Tipp emphasized that no single clinician integrated her dermatologic, gastrointestinal, allergic, and neuropsychiatric symptoms into a unifying diagnosis.

“When you go to a GI doctor for the stomach pain or the diarrhea that you’re having, they don’t ask you about your skin,” Tipp said.

She also emphasized the psychological burden of the rare disease, including stigma around mental health symptoms during mast cell flares and the fear of not being taken seriously by clinicians unfamiliar with systemic mastocytosis.

Financial toxicity compounded the strain. High-dose antihistamines, mast cell stabilizers, and other supportive therapies were costly, leading her to ration medications at times. She urged clinicians to proactively discuss affordability and encourage transparency around adherence barriers.

Ultimately, Tipp enrolled in a clinical trial of avapritinib (Ayvakit; Blueprint Medicines) at the University of Alabama at Birmingham after an oncologist recognized the molecular rationale for KIT inhibition. Within 6 to 8 months, she experienced meaningful improvement across cutaneous and systemic domains, with gradual fading of hyperpigmented lesions and substantial reduction in anaphylactic episodes.

Now a vocal advocate, Tipp encourages dermatology clinicians to consider systemic mastocytosis in patients presenting with recurrent urticaria, flushing, unexplained brown macules, and systemic symptoms. She emphasized the value of clinician transparency—acknowledging knowledge gaps while committing to further investigation—and the importance of moving beyond isolated symptom management to a comprehensive, multidisciplinary approach.

“I would much rather have a doctor… say, ‘I don’t know, but I promise I’m going to learn about it,’ than to pretend,” Tipp said.

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at [email protected].